Skip to main content
Kangmei Pharmaceutical Co.,Ltd logo

Kangmei Pharmaceutical Co.,Ltd — Investor Relations & Filings

Ticker · 600518 ISIN · CNE0000017M1 LEI · 3003006FRNBUUTVKBB50 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,369 across all filing types
Latest filing 2025-11-13 Investor Presentation
Country CN China
Listing Shanghai Stock Exchange 600518

About Kangmei Pharmaceutical Co.,Ltd

http://www.kangmei.com.cn

Kangmei Pharmaceutical Co.,Ltd. focuses on the research, development, production, and distribution of Traditional Chinese Medicine (TCM). The company manages an integrated industry chain that includes herbal cultivation, standardized processing of decoction pieces, and the manufacturing of patent medicines. Its offerings extend to health supplements, medical devices, and functional foods. A key component of its operations is the management of large-scale TCM trading centers and logistics hubs designed to standardize the trade of medicinal materials. Through its "Internet + Healthcare" initiatives, the company provides digital health management and pharmaceutical supply chain services, catering to medical institutions, retail pharmacies, and individual consumers.

Recent filings

Filing Released Lang Actions
康美药业关于召开2025年第三季度业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about the scheduling and details of a 2025 third quarter earnings explanation meeting (业绩说明会) for 康美药业股份有限公司. It provides the date, time, location, participation method, and contact information for the meeting. It references that the company has already released the 2025 third quarter report on October 31, 2025, but this document itself does not contain any financial data or results. It is clearly an announcement about an upcoming earnings call or presentation rather than the earnings release itself or a transcript. The document length is short (1458 characters) and it mainly serves to inform investors about the meeting logistics and how to participate. Therefore, this fits best as an Investor Presentation (IP) announcement or related to an earnings call event. However, since it is announcing the earnings explanation meeting (a presentation to investors about quarterly results), the best classification is Investor Presentation (IP).
2025-11-13 Chinese
康美药业第十届董事会2025年度第四次临时会议决议公告
Board/Management Information Classification · 95% confidence The document is a board meeting resolution announcement from 康美药业股份有限公司 regarding the approval of the company's 2025 third quarter report. It states that the board meeting was held and the 2025 Q3 report was approved, with a note that the detailed report is disclosed on the stock exchange website. The document itself does not contain the full quarterly report or substantive financial data, but rather announces the board's approval and references the report's publication elsewhere. The document length is short (573 characters), consistent with an announcement rather than the full report. Therefore, this is a Board/Management Information filing (MANG) because it announces board resolutions and meeting outcomes related to management decisions and approvals.
2025-10-30 Chinese
康美药业第十届监事会2025年度第三次临时会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Kangmei Pharmaceutical Co., Ltd. regarding the approval of the company's 2025 third quarter report. It states that the detailed third quarter report is disclosed on the Shanghai Stock Exchange website, indicating this document is an announcement of the meeting resolution rather than the report itself. The document length is short (533 characters), and it does not contain actual financial data or the full report content. Therefore, it fits best as a Regulatory Filing (RNS) since it is a formal announcement related to corporate governance and report approval but not the report itself.
2025-10-30 Chinese
康美药业2025年第三季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2025 Third Quarter Report" of 康美药业股份有限公司, indicating it is a quarterly financial report. It contains detailed financial data including income statement, balance sheet, cash flow statement, and notes on financial performance for the third quarter and year-to-date periods. The report explicitly states it is unaudited and covers the period ending September 30, 2025. The presence of comprehensive financial statements and analysis for a period shorter than a full fiscal year confirms it is an Interim / Quarterly Report. There is no indication that this is merely an announcement or a certification, and the document length and content confirm it is the full report itself, not just a publication announcement or regulatory filing. Therefore, the correct classification is Interim / Quarterly Report (IR). 9M 2025
2025-10-30 Chinese
康美药业关于召开2025年半年度业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about the scheduling and details of a 2025 half-year performance explanation meeting (业绩说明会) for 康美药业股份有限公司. It provides the date, time, location, participation method, and contact information for the meeting. It references the previously published 2025 half-year report but does not contain any financial data or detailed financial analysis itself. The document is short (1455 characters) and serves to inform investors about the upcoming event rather than presenting the report or detailed results. According to the classification rules, such announcements about meetings or presentations are classified as Investor Presentation (IP) if they contain detailed presentations, or as Report Publication Announcement (RPA) if they announce the release of a report. However, this document is specifically about an earnings explanation meeting (业绩说明会), which is a form of investor presentation focused on financial results and Q&A. Therefore, the best fit is Investor Presentation (IP).
2025-10-09 Chinese
康美药业关于收到补偿款的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from 康美药业股份有限公司 regarding the receipt of compensation money related to a property lease and demolition due to a city project. It specifies the amount received, its impact on current period profit and loss, and notes that the final impact will be confirmed by the annual audit. The document is short (655 characters) and serves as a notification of a financial event affecting the company, not a full financial report or audit report. It does not contain detailed financial statements or comprehensive analysis. Therefore, it is best classified as a Regulatory Filing (RNS), which covers miscellaneous announcements that do not fit other specific categories.
2025-09-30 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.